TAM
ALXN

Tocqueville Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tocqueville Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-66,460
Closed -$8.13M – 849
2016
Q4 		$8.13M Buy
66,460
+21,135
+47% +$2.59M 0.1% 218
2016
Q3 		$5.55M Buy
45,325
+6,090
+16% +$784K 0.07% 263
2016
Q2 		$4.58M Sell
39,235
-22,875
-37% -$3.25M 0.05% 304
2016
Q1 		$8.65M Buy
62,110
+12,520
+25% +$1.84M 0.11% 201
2015
Q4 		$9.46M Sell
49,590
-950
-2% -$166K 0.13% 185
2015
Q3 		$7.9M Buy
50,540
+6,315
+14% +$1.15M 0.11% 228
2015
Q2 		$8M Buy
44,225
+2,150
+5% +$371K 0.09% 235
2015
Q1 		$7.29M Buy
42,075
+160
+0.4% +$29K 0.09% 253
2014
Q4 		$7.76M Sell
41,915
-2,025
-5% -$375K 0.08% 243
2014
Q3 		$7.29M Buy
43,940
+575
+1% +$94.4K 0.08% 242
2014
Q2 		$6.78M Buy
43,365
+3,800
+10% +$600K 0.07% 270
2014
Q1 		$6.02M Sell
39,565
-3,440
-8% -$547K 0.08% 228
2013
Q4 		$5.71M Buy
43,005
+1,300
+3% +$156K 0.08% 234
2013
Q3 		$4.84M Buy
41,705
+1,715
+4% +$188K 0.06% 303
2013
Q2 		$3.69M Buy
+39,990
New +$3.85M 0.05% 327

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Tocqueville Asset Management's ALXN Position: Q1 2017 in Review

Tocqueville Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 66,460 shares — an estimated $8.13M sold.

Tocqueville Asset Management first reported a position in ALXN in Q2 2013 and held it in 15 quarters. The position peaked at $9.46M in Q4 2015. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Tocqueville Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Tocqueville Asset Management sold 66,460 Alexion Pharmaceuticals shares in Q1 2017, an estimated $8.13M.
  • Tocqueville Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Tocqueville Asset Management's Alexion Pharmaceuticals position peaked at $9.46M in Q4 2015.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Tocqueville Asset Management's 13F filing for Q1 2017, filed 28 Apr 2017.